The role of olmesartan medoxomil in the management of hypertension

Drugs

Volumn 64, Issue 24, 2004, Pages 2731-2739

  Unger, Thomas ^a   McInnes, Gordon T ^b   Neutel, Joel M ^c   Böhm, Michael ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b WESTERN INFIRMARY   (United Kingdom)

^c Orange County Heart Institute and Research Center   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; RAMIPRIL; VALSARTAN;

ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EUROPE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MYALGIA; NONHUMAN; PAIN; PATIENT COMPLIANCE; REVIEW; RHINITIS; UNITED STATES;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 10844222742     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464240-00002     Document Type: Review

References (44)

1. MacMahon S. Antihypertensive drug treatment: the potential, expected and observed effects on vascular disease. J Hypertens Suppl 1990 Dec; 8 (7): S239-44
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC7 Report. JAMA 2003 May; 289 (19): 2560-722
3. Isles CG, Walker LM, Beevers GD, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986 Apr; 4 (2): 141-56
4. Meissner I, Whisnant JP, Sheps GS, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999 Sep; 34 (3): 466-71
5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003 Jul; 290 (2): 199-206
6. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001 Mar; 37 (3): 869-74
7. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001 Nov; 135 (9): 825-34
8. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
9. Menard J, Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995 Jul; 9 Suppl. 2: S19-23
10. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001 Oct; 38 (4): 827-32
11. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerability. Blood Press 1997 Sep; 6 (5): 313-7
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep; 345 (12): 861-9
13. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar; 359 (9311): 995-1003
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep; 345 (12): 851-60
15. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998 Jul-Aug; 20 (4): 671-81
16. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001 Dec; 23 (12): 1999-2010
17. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995 Oct; 285 (2): 181-8
18. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41 (5): 515-27
19. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001 Jun; 19 (1): S41-8
20. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr; 87 Suppl. 8A: 37C-43C
21. Neutel JM, Elliott WJ, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002 Sep-Oct; 4 (5): 325-31
22. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003 May; 21 (2): S43-6
23. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 Suppl. 6: S9-15
24. Püchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel antiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997; 15: 1809-12
25. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001 Sep-Oct; 3 (5): 283-91
26. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2003; 362: 1527-35
27. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001 Jun; 19 Suppl. 1: S49-56
28. Neutel JM. Optimal blood pressure control: contribution of olmesartan. Presentation at the 13th European Meeting on Hypertension; 2003 Jun 13-17; Milan
29. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004 Mar; 17 (3): 252-9
30. Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther 2004; 26 Suppl. A: A21-7
31. Kannel WB. Framingham Study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995 Sep; 18 (3): 181-96
32. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996 Jan; 334 (1): 13-8
33. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002 Jan; 89 (2A): 3A-9A
34. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000 Sep; 36 (30): 646-61
35. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure: Valsartan Heart Failure Trial Investigators. N Engl J Med 2001 Dec; 345 (23): 1667-75
36. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003 Aug; 108 (6): 684-90
37. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003 Jul; 163 (13): 1555-65
38. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep; 345 (12): 870-8
39. Lithell H, Hansson L, Skoog I, et al. The Study On Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 May; 21 (5): 875-86
40. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003 May; 14 (5): 1212-22
41. Ohki R, Yamamoto K, Ueno S, et al. Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes. Cardiovasc Drugs Ther 2003 May; 17 (3): 231-6
42. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr; 87 Suppl. 8A: 33C-6C
43. 1 receptor antagonist. J Hypertens Suppl 2001 Jun; 19 Suppl. 1: S3-14
44. Böhm M. Shortening the way to optimal blood pressure control. Presentation at the 13th European Meeting on Hypertension; 2003 Jun 13-17; Milan